
Please try another search
Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.15 on revenue of $533.8M. Analysts polled by Investing.com anticipated EPS of $0.0257 on revenue of $520.35M.
Biomarin Pharma shares are up 0.06% from the beginning of the year, still down 6.16% from its 52 week high of $94.20 set on February 10. They are outperforming the Nasdaq which is down 19.03% from the start of the year.
Biomarin Pharma shares lost 0.21% in after-hours trade following the report.
Biomarin Pharma's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
SHANGHAI (Reuters) -China's CATL said on Friday it would build a 7.3 billion euro ($7.6 billion) battery plant in Hungary, Europe's largest so far, as the world's biggest electric...
By Senad Karaahmetovic Shares of Expensify (NASDAQ:EXFY) have tumbled nearly 14% in premarket trading after the software company reported weak Q2 results. EXFY reported revenue...
By Eduardo Baptista BEIJING (Reuters) -A hacker claims to have obtained the personal information of 48.5 million users of a COVID health mobile app run by the city of Shanghai,...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.